Innova Captab Limited has informed the Exchange about Investor Presentation
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Innova Captab filed its investor presentation ahead of the May 20, 2025 earnings call covering Q4 and full-year FY25 results. For FY25, revenue from operations rose 15% to ₹1,243.7 crores, EBITDA grew 19% to ₹198.2 crores (margin 15.9%), and profit after tax jumped 36% to ₹128.3 crores (margin 10.3%), with EPS at ₹22.41 versus ₹18.66 last year. In Q4 alone, revenue grew 20% YoY to ₹314.7 crores, EBITDA rose 17% to ₹51.1 crores, while PAT was up a modest 3% to ₹29.6 crores due to higher depreciation and finance costs from the new Jammu plant. All four business segments grew — CDMO (+6%), Domestic Branded Generics (+21%), International Branded Generics (+25%), and Sharon Bio-Medicine (₹196.8 crores). The recently commissioned Kathua, Jammu plant (over ₹480 crore investment, started January 2025) is now contributing and is expected to scale up over 2-3 years, with the company also highlighting capacity expansion, R&D additions, and acquisition-led growth as key strategies going forward.
Strong FY25 results with broad-based growth across segments and a 36% jump in annual profit signal solid operational momentum. The new Jammu plant adds significant future capacity, though near-term margins are weighed down by depreciation from this investment — shareholders should watch ramp-up progress and segment-wise growth in coming quarters.